Journal
TRIALS
Volume 18, Issue -, Pages -Publisher
BMC
DOI: 10.1186/s13063-017-1976-6
Keywords
Statistical analysis plan; Eczema; Paediatric; Atopic dermatitis; Anti-IgE; Omalizumab; Randomised controlled trial; Xolair
Categories
Funding
- National Institute for Health Research Efficacy and Efficacy and Mechanism Evaluation Programme (NIHR EME) [11/14/24]
- Guy's and St. Thomas' Charity
- Asthma UK [MRC-AsthmaUKCentre, MRC-Asthma UK Centre] Funding Source: researchfish
- Medical Research Council [G1000758, MC_PC_14136, G1000758B] Funding Source: researchfish
- MRC [MC_PC_14136] Funding Source: UKRI
Ask authors/readers for more resources
Background: The Atopic Dermatitis Anti-IgE Paediatric Trial (ADAPT) is a trial to determine the clinical efficacy and safety of omalizumab for children with severe atopic eczema. This article describes the detailed statistical analysis plan for the ADAPT as an update to the published protocol and is submitted prior to knowing all outcomes. Method and design: The ADAPT is a randomised, double-blind, placebo-controlled trial with a primary objective to determine whether anti-IgE reduces eczema severity as assessed by the validated eczema score (objective SCORAD) after 24 weeks of treatment in children with severe eczema. This articles outline the overall analysis principles including considerations on sample definition in each analysis, missing data, and adjusted covariates. Comparability and representativeness of the randomised groups, primary and sensitivity analyses of the primary and secondary outcomes as well as subgroup analysis are described. Results: This prespecified statistical analysis plan has been developed to comply with international guidelines which will increase the transparency of the data analysis for the ADAPT.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available